Accueil・Liste d'Actions・Galectin Therapeutics Inc

Galectin Therapeutics Inc

Ouvert

SecteurSoins de santé

3.41 -2.57

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.18

Max

3.54

Chiffres clés
By Trading Economics
Revenu	454K -5M
BPA	-0.08
Employés	9
EBITDA	474K -3M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+211.61% upside

Dividendes
By Acuity
Prochains Résultats	14 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	169M 315M
Ouverture précédente	5.98
Clôture précédente	3.41

Sentiment de l'Actualité

By Acuity

40%

60%

134 / 340 Classement par Healthcare

Galectin Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 août 2026, 20:02 UTC

Galectin Therapeutics Inc shares are higher during Thursday's session, reflecting strong trading activity and unusually high market volume, despite lacking specific company news.

12 août 2026, 19:42 UTC

Galectin Therapeutics Inc shares are rising Wednesday amid high trading volume, maintaining an upward trend since Tuesday's close despite pulling back from earlier session highs.

11 août 2026, 19:56 UTC

Galectin Therapeutics Inc shares are lower today amid routine fluctuations and no specific news. The stock is near the lower end of its one-month trading range.

10 août 2026, 20:02 UTC

Galectin Therapeutics Inc shares are lower today, reflecting a significant decline since Friday amid high trading volume and cautious investor sentiment following a weak jobs report.

8 août 2026, 00:01 UTC

Galectin Therapeutics Inc shares are higher in after-market hours, reflecting strong buying activity. The stock has recovered from an early session low.

7 août 2026, 23:01 UTC

Galectin Therapeutics Inc shares are higher in after-market hours, recovering from earlier losses amid favorable broader market conditions and a declining unemployment rate.

6 août 2026, 22:06 UTC

Galectin Therapeutics Inc shares are lower in after-market trading, continuing a trend below their 20-day moving average amid a significant decline since last month.

5 août 2026, 23:02 UTC

Galectin Therapeutics Inc shares are higher in after-market trading, despite no specific news driving the movement. The stock showed significant volatility during the session.

4 août 2026, 20:03 UTC

News

Galectin Therapeutics announced a $105.8 million debt-to-equity conversion but shares are lower today after an early peak. Trading volume is unusually high.

3 août 2026, 19:46 UTC

Galectin Therapeutics Inc is higher today, continuing an upward trend since Friday's close, despite pulling back from a session high. No specific news was identified.

31 juil. 2026, 21:51 UTC

Galectin Therapeutics Inc is lower in after-market trading, influenced by broader market trends. The asset has faced three consecutive sessions of declines.

30 juil. 2026, 20:10 UTC

Galectin Therapeutics Inc is lower today, breaking a trend of higher daily closes. Increased market volume accompanies the decline amid broader market volatility.

29 juil. 2026, 18:58 UTC

Galectin Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday's close. The stock remains below its 20-day moving average.

28 juil. 2026, 17:46 UTC

Galectin Therapeutics Inc shares are lower today, continuing a decline since Monday's close, amid broader market caution following significant drops in Asian indices.

27 juil. 2026, 16:32 UTC

Galectin Therapeutics Inc shares are lower today, reflecting a notable decline since Friday. The stock has seen unusually high trading volume amid broader market sentiment.

24 juil. 2026, 20:02 UTC

Galectin Therapeutics Inc is lower today, marking its ninth consecutive session of declines. The stock remains below its 20-day moving average.

22 juil. 2026, 19:01 UTC

Galectin Therapeutics Inc. shares are trading lower, following a peak earlier in the session. High trading volume indicates increased investor activity.

21 juil. 2026, 17:16 UTC

Galectin Therapeutics Inc. shares are lower today, continuing a five-session decline and trading significantly below the 20-day moving average. No specific news was identified.

20 juil. 2026, 20:06 UTC

Galectin Therapeutics Inc shares are lower today, continuing a trend of five consecutive daily declines amid broader market volatility linked to geopolitical tensions.

Comparaison

Variation de prix

Galectin Therapeutics Inc prévision

Objectif de Prix

By TipRanks

211.61% hausse

Prévisions sur 12 Mois

Moyen 11 USD 211.61%

Haut 11 USD

Bas 11 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

Achat

Maintien

Vente

Basé sur 1 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

134 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.